Humana and BlackRock: the promise behind the clinics

The financial partner is set to change. CenterWell is to keep operating the clinics. On 13 October 2026, Humana announced that funds and accounts managed by HPS, part of BlackRock, would acquire Welsh, Carson, Anderson & Stowe’s interest in a network of nearly 150 senior primary-care clinics. Completion is expected in the fourth quarter, subject to closing conditions and regulatory approvals. ^[1]

Humana’s announcement emphasises a lighter balance sheet. The outgoing partner held an option allowing it to require a buyout of its interest; the replacement arrangement removes that right. The regulatory disclosure published the same day adds a crucial detail: CenterWell has agreed to minimum-return protections for the incoming investor. Those protections will create a derivative, a financial commitment whose value here depends on the protected return. It will be recorded at fair value on Humana’s balance sheet. ^[2]

That is the transaction’s revealing feature. One commitment disappears, another takes shape, and the care business continues. Understanding the risk passed to investors requires following the exit rights, the assumptions that determine their value and the resources available to honour them. Public documents disclose much of that architecture. The size of the new protection remains an open question.

The $2.8 billion is the seller’s stake value

The announced figure, approximately $2.8 billion, is the value of WCAS’s existing equity ownership. The proposed purchase replaces that shareholder with HPS-managed investors. CenterWell would retain a minority interest and responsibility for running the clinics. The release also anticipates additional capital over the next two years for operations, new locations and acquisitions, without specifying an amount. ^[1]

These are two different movements of capital. Buying an existing shareholder’s interest provides liquidity to that shareholder. Funding a clinic’s opening supports the operating business. Combining the two would manufacture an inflow to Humana or the clinics that the announcement does not establish. Reuters reports the same distinction in an analyst’s interpretation: the $2.8 billion refers to WCAS’s stake rather than announced sale proceeds for Humana. ^[11]

The identity of the buyer also deserves precision. The agreement involves funds and accounts managed by HPS. BlackRock completed its acquisition of the HPS manager on 1 July 2025 and integrated it into its private-financing activities. Describing the transaction as “BlackRock investing” compresses an investment-management chain. The documents reviewed do not identify all the participating vehicles or their underlying investors. ^{[2] [9]}

That chain matters for incentives. A manager selects and structures an investment; participating vehicles provide the capital under their own commitments. The manager’s name identifies an intermediary. It does not, by itself, reveal the capital’s duration, any leverage or its capacity to finance further operating losses. Those questions require the relevant vehicles’ documents. Our reading of Apollo’s accounting perimeter develops the distinction between accounting boundaries and economic dependencies.

Method and scope

Transaction announced on 13 October 2026; closing is expected in the fourth quarter, subject to conditions. The approximately $2.8 billion is the announced value of WCAS’s stake, not the enterprise value of the full network or sale proceeds for Humana. Expected additional capital over two years is not quantified. Arrow widths do not encode amounts.

An exit was built into the clinics’ original financing

The partnership began in February 2020. Humana and WCAS announced a venture to develop primary-care centres for Medicare patients under the then-current Partners in Primary Care brand. The financial investor held a majority interest and Humana a minority. The operator received management fees with performance incentives. Options arranged staged buyouts over five to ten years. ^[6]

A second venture extended the model in May 2022. The financial partner would help fund new locations and support them through to profitability. For that second arrangement, Humana’s purchase rights began in 2028, or five years after each cohort opened. WCAS’s rights to require a buyout began in 2030, or seven years after opening. A cohort means clinics developed in the same wave. ^[5]

A call option gives the prospective buyer the initiative. A put gives that initiative to the seller, subject to the agreed terms. For an operator, this changes the funding calendar. It may choose to buy an established business, or it may need to prepare financing for a buyout requested by its partner. Clinic development and shareholder liquidity become contractually connected.

The 2022 dates do not describe the entire legacy portfolio. Humana’s June 2026 report said the first two cohorts could already be called in 2026, at an estimated price of $1.0 billion to $1.6 billion. That was a projected exercise price for those cohorts, distinct from the value of the whole partner stake and from the accounting liability. ^[3]

The proposed HPS structure resets the schedule. CenterWell may begin buying clinics at its election in 2028. If any remain in the venture at the end of 2033, the financial partner can elect to exit through a sale process for those remaining locations. CenterWell has a right of first offer, or ROFO. The filing describes a first offer, which should not be read as an automatic right to match every subsequent bid. ^[2]

Method and scope

The June 2026 report identifies 2026 call rights for the first two legacy cohorts. The May 2022 announcement describes initial rights for the second venture: calls in 2028 or five years after opening; puts in 2030 or seven years after opening. The new deal provides optional purchases from 2028 and a possible sale process after end-2033 if clinics remain. CenterWell’s first-offer right is not a general right of first refusal. The desktop chart shares an annual axis; the mobile layout is not to time scale.

How a buyout promise becomes a balance-sheet liability

At 30 June 2026, Humana valued the WCAS put liability at $1.6 billion. Its own call options were recorded separately as a $20 million asset. The positions sit in other long-term liabilities and assets, respectively. Changes in their fair value flow through the income statement under other expense, net. ^[3]

The put liability had been $883 million at the end of 2024 and $1.4 billion at the end of 2025. The sequence shows the growing significance of the reported commitment. It is not a controlled comparison holding the portfolio and assumptions fixed: the network develops, forecasts change and exercise dates draw closer. Separating those effects would require a decomposition that these figures do not provide. ^{[4] [3]}

Fair value answers a measurement question at a particular date. It estimates an instrument’s value given its terms and possible outcomes. It therefore differs from the total price paid to acquire clinics: a buyer making that payment also receives an economic asset. It is also distinct from a certain debt maturity or a maximum possible loss.

Humana uses Monte Carlo simulation, exploring many possible paths to value the options. Inputs include long-term revenue assumptions, enterprise value, volatility and credit assumptions. Important inputs are estimated rather than directly observed in a market. Balance-sheet sensitivity therefore depends both on the contract and on the future projected for the clinics. ^[3]

One feature makes the legacy arrangement especially instructive. The options use a revenue exit multiple and provide WCAS with a minimum return if exercised. The June disclosure lists multiples of 1.5 to 2.5 times revenue across the instruments. The underlying enterprise valuation, meanwhile, uses discounted future cash flows. ^[3]

The potential mismatch is straightforward. A business can generate more revenue while producing less cash, for example when medical expenses increase faster than payments received. A revenue-based exercise formula and a cash-flow-based business value can then move differently. This explains a vulnerability in the legacy mechanism; it does not reconstruct any particular exercise price or the new agreement’s formula.

Method and scope

USD millions, fair values at the stated reporting dates. 2025 annual accounts, Note 6; unaudited June 2026 interim accounts, Note 5. The 10-K gives $883 million; $1.4 billion and $1.6 billion are reported rounded amounts. The portfolio and assumptions vary. The separate call-option asset is $20 million in June 2026. These are neither total purchase prices nor debt repayments. No zero amount is assigned to the new derivative.

Return protection preserves a link to CenterWell

The press release refers to protections for BlackRock. The 8-K specifies their nature: minimum-return protections that create the new derivative. Some financial linkage will therefore survive removal of the put. Humana expects a significant reduction in liabilities associated with the arrangement, but discloses neither the size of that reduction nor the new instrument’s initial fair value. ^[2]

Knowing that protection exists does not reveal its contract. The reviewed documents omit its rate, calculation period, treatment of past distributions, triggers, caps, the legally liable entities and settlement mechanics. Describing it as a full capital guarantee would go beyond the disclosure, as would concluding that Humana retains all of the downside.

A generic example can still explain the transfer. Suppose an investor is promised a top-up to 110 units at a single settlement date. If investment proceeds are 60, the counterparty contributes 50. At 100, it contributes 10. At 140, no top-up is required. This fictional exercise ignores tax, fees, interim distributions and discounting. It also assumes that the protection provider can pay. It does not reproduce the HPS agreement.

The investor remains interested in the business succeeding. Below the example’s protected threshold, however, part of its exposure shifts towards the party promising the top-up. It now has both a stake in an operating business and a dependence on a counterparty. That counterparty’s resilience becomes particularly important in the outcomes in which protection would be needed. Our investigation of counterparty risk in pensions transferred to Bermuda examines the dependence on the party that must honour the commitment.

Method and scope

Teaching simulation unrelated to the confidential parameters of the HPS agreement. One settlement date; an arbitrary floor of 110. Top-up = the maximum of zero and 110 minus proceeds; total = proceeds plus top-up. Assumes a solvent counterparty, no cap, fees, tax, interim distributions or discounting. The chart is a payment function, not market observations, a probability or a contractual return rate. The 8-K establishes only that minimum-return protections exist in the transaction.

The distinction between a current valuation and adverse outcomes should guide the reading of the eventual balance sheet. Protection covering only certain events can have a relatively low accounting value while creating a meaningful liquidity requirement if those events occur. Conversely, demanding triggers, narrow caps or strong clinic performance might leave little residual risk. Access to the full agreement and a first reported valuation would help distinguish between these possibilities.

The 13 October filing inventory contains the 8-K, an attached press release and technical files. It does not attach the full joint-venture agreement. The public record establishes the protection’s existence more firmly than its scale. ^[10]

Clinic revenue also pays for taking medical risk

Connecting the financing to the business requires returning to what CenterWell does. These are primary-care operations providing follow-up and coordination, rather than simply a property portfolio. The annual report describes arrangements under which the business typically receives a per-member, per-month payment for standing ready to deliver and organise specified healthcare services. The expenses it assumes vary with the contract. ^[4]

That fixed payment is known as capitation. Where it covers a basket of care, the provider bears the risk that actual medical spending exceeds the amount received. The organisation can invest in chronic-disease follow-up, appointments and coordination to improve health and reduce avoidable complications. CMS, the federal agency administering Medicare, describes these goals in its account of value-based care, with quality and patient experience central to the model. ^{[4] [7]}

Clinic economics therefore take time to develop. Hiring a team and organising care come before some of the expected benefits of coordination. The legacy investor was explicitly intended to finance centres through to profitability, according to the 2022 announcement. Removing a binding exit route can give the operator more time to reach a sustainable scale and operating performance. That is the strongest case for the replacement arrangement. ^[5]

The next question is where the benefit accrues. Preventing a complication requiring hospital care can protect a patient’s health and reduce payer expenditure; the clinic’s share of that benefit depends on its contract. Financial returns alone reveal little about appointment access, continuity of care or patient health. Those require separate observations.

Method and scope

General capitation mechanism described in the 2025 10-K, and objectives of value-based care described by CMS. The scope of costs assumed and any protection vary by contract. This diagram does not reproduce a specific contract in the transferred network, measure clinical outcomes or assume all patients have the same payer. Buildings and people are schematic illustrations, not identified sites or individuals.

The clinics do not exclusively serve Humana members. Company documents describe a payer-agnostic model and risk-sharing arrangements involving different Medicare plans. That can diversify commercial relationships, while also exposing the provider to terms negotiated with outside insurers. The annual report explicitly identifies the risk that the cost of a basket of services exceeds the reimbursement received. ^[4]

Assessing the transaction would ideally require cohort-level data: operating history, patients actually served, medical expenses assumed, cash generation and quality. The entire CenterWell segment also includes pharmacy and home-care operations. Using its result as evidence that the clinics in this transaction are profitable would erase that difference in scope. ^[3]

A common shock can reach both sides of the protection

Public payment rules also shape clinic revenue. In 2026, CMS completes the three-year transition to the 2024 CMS-HCC risk-adjustment model for organisations other than PACE. The model adjusts payments for beneficiary characteristics. It affects Medicare Advantage plans first; transmission to providers then depends on their contracts. ^[8]

Humana’s interim accounts explain that the final phase of this revision affects its primary-care business, with mitigation measures offsetting some of the pressure. That establishes exposure to the mechanism, without isolating the effect on the nearly 150 clinics involved in the new partnership. ^[3]

Financial protection should therefore be read alongside the operator’s own business risks. In an adverse scenario, payment changes or medical-cost developments could weigh on clinic cash flows and exit values. Depending on the terms, they might also push the investment closer to the outcomes covered by the protection. The group to which CenterWell belongs can itself be exposed to the same healthcare environment. The precise scope of recourse and any parent-company guarantees would require the contracts. This is an economic inference to test, not evidence that any protection is about to be triggered.

Dividing equity among investors diversifies the holders. Diversifying the underlying risk drivers is a separate task. If equity values, exit projections and protections depend on the same pool of medical revenue, losses can remain correlated across different legal structures. The reviewed public data do not quantify that correlation for the HPS arrangement, still less establish a systemic threat.

Method and scope

Conditional economic scenario based on the 8-K, payment and medical-cost risks described by Humana, and the CMS-HCC 2024 transition completed in 2026 except for PACE organisations. The diagram predicts no protection payout. It assumes neither an unlimited Humana guarantee to funds nor a quantified correlation. Dashed lines show the conditional protection relationship; triggers and scope are not publicly detailed.

The exit route after the end of 2033 also creates exposure to the market value of the remaining clinics. A sale price would depend on a buyer and the available financing conditions, under the agreed process. CenterWell’s first-offer right keeps it involved, while later steps depend on contractual terms. This market-sale route could represent a substantial transfer of risk to investors, depending on the extent of their return protections. ^[2]

Three different ways to judge the outcome

Closing will first generate accounting entries. The 8-K maintains Humana’s adjusted earnings guidance for 2026 while flagging possible changes to its US GAAP earnings guidance, including from removing the legacy put. The company also says its third-quarter financial-close procedures are still under way. ^[2]

An accounting effect can therefore become visible before any operating improvement can be observed. The second measure is liquidity: capital committed to the clinics, possible acquisitions and payments that protection might require. The third concerns healthcare delivery and whether clinic cohorts can operate sustainably. All three describe complementary dimensions of the same business. Our analysis of risk transmission between property funds, life insurance and banks also distinguishes asset value, payment obligations and available cash.

A favourable assessment would be supported by less restrictive buyout commitments, genuinely available funding and tightly bounded residual protection. More resilient clinics and maintained or improved care outcomes would strengthen that assessment over time. Broad protection, sensitive to operating difficulties and poorly captured in liquidity monitoring, would limit the economic significance of the announced balance-sheet relief.

As of 14 October 2026, the public record establishes a concrete change: the announced arrangement would replace the legacy right to sell to Humana with return protections, while preserving an exit route for the investor. The amount of risk actually transferred remains to be measured. The missing formula requires that qualification. The new derivative makes continued attention to the balance sheet essential.

Sources and method

Documentary research closed on 14 October 2026. The 13 October release and 8-K were compared with the 2025 annual accounts, June 2026 interim accounts and the historical 2020 and 2022 announcements. CMS materials were used to verify payment rules and care-coordination objectives. The full English Reuters text, read in Euronext’s republication, provides a contextual cross-check, without independent validation of contractual protections; the original Reuters page was inaccessible.

Specific commitments rely on Humana’s disclosures as a party to the transaction. We obtained neither the full HPS agreement nor standalone accounts for the new venture, and conducted no interviews with the parties. No clinical outcome, protected return rate, fund leverage or new derivative value is reconstructed. Company forecasts remain attributed to Humana. The protection example is entirely fictional; transmission diagrams illustrate conditional mechanisms. In the documents reviewed, the transaction remains announced and subject to closing.

1. Humana, new joint-venture announcement. 2026-10-13. Company release; ownership, options and closing paragraphs. Interested-party disclosure. Closing, future capital and expected benefits are conditional.
2. Humana, Form 8-K, 13 October 2026. 2026-10-13. Item 7.01, Blackrock Joint Venture and 2026 Earnings Guidance. Key disclosure: minimum-return protections and a new derivative. Rate, formula, caps and initial fair value are not disclosed. Humana’s PDF copy.
3. Humana, Form 10-Q for 30 June 2026. 2026-07-29. Note 5, Put and Call Options Measured at Fair Value, printed pp. 18–19; CenterWell discussion, pp. 44–45. Unaudited interim statements. June marks predate the new arrangement; they are not closing-date estimates.
4. Humana, 2025 Form 10-K. 2026-02-19. Business: Primary Care and Capitation; Risk Factors; notes 2, 4 and 6, particularly p. 89. CenterWell is broader than the joint venture; segment results do not measure the venture’s own profitability.
5. Humana–WCAS, second joint-venture announcement. 2022-05-16. Committed-capital, management-fee and cohort-option paragraphs. Schedule applies to the second venture. Construction targets and committed capital are not completed investment.
6. Humana–WCAS, initial partnership announcement. 2020-02-03. Majority/minority ownership, operations and options over five to ten years. Historical disclosure under the Partners in Primary Care brand; not the 2026 HPS terms.
7. CMS, Value-Based Care. 2025-02-27. First posted 14 August 2023; revised 27 February 2025. Definitions and care coordination. Explains the care model’s goals; does not evaluate outcomes at these clinics.
8. CMS, final 2026 Medicare Advantage payment announcement. 2025-04-07. Part C Risk Adjustment Model; completion of the 2024 CMS-HCC transition, excluding PACE. Plan-payment rules; provider-contract effects vary. Does not quantify this venture’s revenue impact.
9. BlackRock, completion of the HPS acquisition. 2025-07-01. Creation of Private Financing Solutions; financing activities and HPS description. Manager disclosure. It does not identify the vehicles or end investors funding the clinic transaction.
10. SEC EDGAR, 8-K filing inventory. 2026-10-13. Accession 0000049071-26-000060: report, Exhibit 99.1 and technical files. This filing does not attach the complete joint-venture agreement. It does not prove that no other or later publication exists.
11. Reuters via Euronext, BlackRock replaces WCAS in joint venture with Humana senior clinics. 2026-10-13. News report and analyst interpretation of the WCAS stake value. Full Reuters text republished by Euronext; original Reuters page inaccessible. Secondary cross-check, without independent contractual review or audit of return protections.